Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2020-2030

  Chabot, G G ^a   Armand, J P ^a   Terret, C ^a   de Fornit, M ^a   Abigerges, D ^a   Winograd, B ^a   Igwemezie, L ^a   Schacter, L ^a   Kaul, S ^a   Ropers, J ^a   Bonnay, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOFOS; ETOPOSIDE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; HUMAN; LEUKOPENIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 8944232103     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2020     Document Type: Article

References (41)

1. Bender RA, Hamel E, Hande KR: Plant alkaloids, in Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 253-275
2. Issell BF, Crooke ST: Etoposide (VP-16-213). Cancer Treat Rev 6:107-124, 1979
3. Radice PA, Bunn PA, Ihde DC: Therapeutic trials with VP-16-213 and VM-26: Active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rev 63:1231-1239, 1979
4. Schmoll H: Review of etoposide single-agent activity. Cancer Treat Rev 9:21-32, 1982
5. Vogelzang JJ, Raghavan D, Kennedy B: VP-16-213 (etoposide): The mandrake root from Issyk-Kul. Am J Med 72:136-144, 1982
6. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al: Etoposide (VP-16-213): Current status on an active anticancer drug. N Engl J Med 312:692-697, 1985
7. Bosl G, Yagoda A, Golbey RB, et al: Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 78:423-428, 1985
8. Greco FA, Johnson DH, Hande KR, et al: High dose etoposide (VP-16) in small cell lung cancer. Semin Oncol 12:42-44, 1985 (suppl)
9. Cavalli F, Sonntag RW, Jungi F, et al: VP16-213 monotherapy for remission induction of small cell lung cancer: A randomized trial using three dosage schedules. Cancer Treat Rep 62:473, 1978
10. Rozencweig M, Von Hoff DD, Henney JE, et al: VM26 and VP16-213: A comparative analysis. Cancer 40:334-342, 1977
11. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333-1340, 1989
12. Stahelin H: Activity of a new glycosidic lignan derivative (VP16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 9:215, 1973
13. D'Incalci M, Farina P, Sessa C, et al: Pharmacokinetics of VP-16-213 given by different administration methods. Cancer Chemother Pharmacol 7:141-145, 1982
14. Stewart DJ, Nundy D, Maroun J. et al: Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69:269-273, 1985
15. Smyth R, Pfeffer M, Scalzo A, et al: Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12:48-51, 1985 (suppl 2)
16. Carney DN: The pharmacology of intravenous and oral etoposide. Cancer 67:299-302, 1991
17. Cunningham D, McTaggart L, Soukop M, et al: Etoposide: A pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother 3:95-99, 1986
18. Hande KR, Krozely MG, Greco FA, et al: Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374-377, 1993
19. Slevin ML, Joel SP, Whomsley R, et al: The effect of dose on the bioavailability of oral etoposide: Confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24:329-331, 1989
20. Rose WC, Basler GA, Trail PA, et al: Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30. Invest New Drugs 8:S25-S32, 1990
21. Budman DR, Igwemezie LN, Kaul S, et al: Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. J Clin Oncol 12:1902-1909, 1994
22. Fields SZ, Igwemezie LN, Kaul S, et al: Phase I study of etoposide phosphate (Etopophos) as a 30-minute infusion on days 1, 3, and 5. Clin Cancer Res 1:105-111, 1995
23. Sessa C, Zucchetti M, Cerny T, et al: Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13:200-209, 1995
24. Shah VP, Midha KK, Dighe S, et al: Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies (conference report). J Pharmaceut Sci 81:309-312, 1992
25. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
26. Rowland M, Tozer RN: Clinical pharmacokinetics: concepts and applications (ed 2). Malvern, PA, Lea & Febiger, 1989
27. Marzola M, Zucchetti M, Colombo N, et al: Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 4:517-510, 1993
28. Taal BG, Beijnen JH, Teller FGM, et al: Bioavailability of oral etoposide in gastric cancer. Eur J Cancer 30A:420-421, 1994 (letter)
29. Pinkerton CR, Dick G, Aherne GW: 24-Hour plasma etoposide profile after oral and intravenous administration in children. Eur J Cancer 29A:1479-1481, 1993
30. Allen LM, Creaven PJ: Comparison of human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11:697-707, 1975
31. Arbuck SG, Douglass HO, Crom WR, et al: Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4:1690-1695, 1986
32. Creaven PJ, Allen LM: EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:221-226, 1975
33. Evans WE, Sinkule JA, Crom WR, et al: Pharmacokinetics of teniposide (VM-26) and etoposide (VP-16-213) in children with cancer. Cancer Chemother Pharmacol 7:147-150, 1982
34. Hande KR, Wedlund PJ, Noone RM, et al: Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44:379-382, 1984
35. Holthuis J, Postmus P, Van Oort W, et al: Pharmacokinetics of high-dose etoposide (VP-16-213). Eur J Cancer Clin Oncol 22:1149-1155, 1986
36. Köhl P, Köppler H, Schmidt L, et al: Pharmacokinetics of high-dose etoposide after short-term infusion. Cancer Chemother Pharmacol 29:316-320, 1992
37. Sinkule JA, Hutson P, Hayes FA, et al: Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44:3109-3113, 1984
38. de Jong RS, Prins CW, Vranken A. et al: Randomized pharmacokinetic study of oral etoposide phosphate and oral etoposide in patients with a solid tumor on a daily times five schedule. Ann Oncol 5:188, 1994 (suppl 5, abstr 451)
39. Desoize B, Woirin V, Legros M, et al: Reduced oral etoposide bioavailability in patients with advanced cancer of the head and neck. J Natl Cancer Inst 84:348-350, 1992
40. Thompson DS, Greco A, Miller AA, et al: A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin Pharmacol Ther 57:499-507, 1995
41. Brooks DJ, Srinivas NR, Alberts DS, et al: Phase I and pharmacokinetic study of etoposide phosphate. Anticancer Drugs 6:637-644, 1995